CD274 and cancer: Immunotherapy, particularly PD‐1/PD‐L1 antibodies, has shown remarkable efficacy in various solid tumors.[4] Nevertheless, its application in PDAC has encountered significant challenges and disappointing outcomes.[4] This predicament is associated with the intricate immunosuppressive tumor microenvironment of PDAC that shields cancer cells from effective cytotoxic immune responses.[4] In conjunction with our previous findings, we hypothesized that targeting PPY‐induced iCAFs could potentially enhance the efficacy of PD‐1 antibody treatment by alleviating the immunosuppressive environment.